Overview and Highlights 

October 2026 was defined by mega-licensing agreements, strategic acquisitions, and continued momentum in the biotech IPO market, with three major partnerships collectively exceeding $30 billion in potential value. Licensing activity was headlined by Roche's second antibody-drug conjugate collaboration with China's Hansoh Pharmaceutical, valued at over $15 billion, Novartis's up-to-$7.8 billion option-and-license agreement with Abogen Biosciences for an mRNA-encoded T-cell engager, and Sanofi and Regeneron's expanded immunology alliance worth up to $8 billion. Obesity and AI-enabled drug discovery remained prominent themes, with Roche's up-to-$1.2 billion deal with Rona Therapeutics for an RNAi obesity candidate and AstraZeneca's up-to-$1.5 billion collaboration with insitro for AI-enabled discovery in metabolic and cardiovascular disease. Strategic M&A was equally active, led by Shionogi's $2 billion acquisition of rare-disease biotech IntraBio, Merck KGaA's $1.3 billion acquisition of Silence Therapeutics, and EQT's landmark $12.1 billion enterprise-value agreement to take molecular diagnostics leader QIAGEN private.  

The IPO market continued to demonstrate resilience, with City Therapeutics ($200M), Iambic Therapeutics ($150M), TRex Bio ($117M), and Retension Pharmaceuticals ($45M) successfully pricing. Private capital remained robust, anchored by landmark fund closes from Forbion (€2.3B) and OrbiMed ($3B), underscoring continued investor appetite for clinical-stage biotech and healthcare innovation. Overall, October reinforced the strength of 2026's biopharma dealmaking environment, with strategic buyers increasingly pursuing differentiated platforms, metabolic disease opportunities, and established life sciences assets to diversify pipelines and accelerate long-term growth.

‍

Life Science Research Tools

1 | EQT Agrees to Acquire QIAGEN in $12.1B Take-Private Deal | PE

EQT Private Equity has agreed to acquire molecular diagnostics and life sciences tools leader QIAGEN in an all-cash public takeover offer valuing the company at approximately $12.1 billion in enterprise value, including net debt. The offer of €46.50 per share represents a 40.3% premium to QIAGEN's unaffected share price, with the company's Supervisory and Managing Boards unanimously supporting the transaction following a comprehensive strategic review. EQT XI will lead the acquisition alongside co-investors Abu Dhabi Investment Authority (ADIA) and Canada Pension Plan Investment Board (CPP Investments), providing QIAGEN with greater flexibility to pursue long-term investments in product innovation, R&D, and growth under private ownership. QIAGEN will retain its existing name, brand, management, and operational footprint, while EQT brings its healthcare investment experience and operational capabilities to support the company's next phase of development. Closing is expected in mid-2027, subject to shareholder acceptance thresholds and regulatory approvals.

‍

Diagnostics

1 | Labcorp to Acquire BioReference Health Assets from OPKO for up to $872M | M&A

Labcorp has agreed to acquire select assets of BioReference Health, a subsidiary of OPKO Health, for $722 million in cash at closing plus up to an additional $150 million tied to revenue from the 4Kscore prostate cancer test. The acquisition includes BioReference's clinical diagnostics, women's health, urology, and corrections testing businesses, along with more than 80 patient service centers, and is expected to generate approximately $250 million in revenue in its first year under Labcorp. Labcorp will also gain the FDA-approved 4Kscore Test, which helps assess the likelihood of aggressive prostate cancer before a biopsy decision. OPKO said the sale will sharpen its focus on its biopharmaceutical business.

2 | Agilent to Acquire Proscia for up to $270M | M&A

Agilent Technologies has agreed to acquire Proscia, a digital pathology software company, in an all-cash transaction valued at $240 million at closing plus up to an additional $30 million tied to future performance milestones. Proscia's Concentriq platform serves as a central operating layer for digital pathology, connecting slide scanners, laboratory information systems, AI tools, and data across clinical and life-sciences customers, and holds FDA 510(k) clearance for primary diagnosis. The acquisition builds on a multi-year distribution agreement the companies struck in 2022 and follows Agilent's $950 million acquisition of Biocare Medical earlier in 2026, further building out its pathology instrumentation and digital software portfolio. The deal is expected to close early in Agilent's fiscal year 2027.

‍

‍

Therapeutics

1 | Roche Returns to Hansoh for Second ADC Pact Worth Over $15B | M&A

Roche has returned to China's Hansoh Pharmaceutical for a second antibody-drug conjugate (ADC) collaboration, a year after their first tie-up, in a deal that could exceed $15 billion. Hansoh will receive $400 million upfront and a further $110 million on the first anniversary of the deal, with the remainder tied to development, regulatory, and commercialization milestones across a broad portfolio of ADC programs, plus tiered royalties on sales. The agreement spans two existing preclinical Hansoh programs plus additional candidates based on Roche-selected targets, with Hansoh leading early development through Phase 1a before Roche assumes responsibility outside Greater China. The deal extends Roche's aggressive China-sourced ADC strategy, following a string of similar partnerships with Chinese biotechs over the past year.

2 | Sanofi Pays Regeneron $1B Upfront in up to $8B Immunology Deal | M&A

Sanofi and Regeneron have expanded their two-decade antibody alliance to jointly develop four next-generation, long-acting immunology antibodies, in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential for up to an additional $7 billion in development, regulatory, and commercial milestone payments; the companies will equally share development and commercialization costs and split future profits from the new programs 50:50 globally. The four assets target IL-13, IL-4, IL-4 receptor alpha, and an IL-4xIL-13 bispecific, building on the type-2 inflammation franchise that produced Dupixent; the lead candidate, REGN20423, is already in Phase 1 testing for atopic dermatitis. Regeneron will lead R&D while Sanofi leads global commercialization, and the companies confirmed they have settled prior collaboration-related litigation.

3 | Novartis Licenses Abogen’s mRNA T-Cell Engager for up to $7.8B | M&A

Novartis has entered a licensing and option agreement with China's Abogen Biosciences worth up to approximately $7.8 billion for ABO2203, an mRNA-encoded CD19xCD3 T-cell engager designed to treat B-cell-mediated autoimmune diseases. Abogen will receive $575 million upfront and is eligible for up to $7.2 billion in additional development, regulatory, and commercial milestones, plus tiered royalties, if Novartis exercises options across Abogen's broader RNA platform. Rather than administering a recombinant T-cell engager, the therapy directs the patient's own cells to produce the molecule in vivo, aiming to deplete disease-driving B cells with potential manufacturing and dosing advantages over conventional approaches. The deal comes weeks after Novartis paused an autoimmune CAR-T program following three patient deaths, underscoring the company's push to diversify its approach to B-cell depletion.

4 | Shionogi Acquires IntraBio for $2B | M&A

Shionogi has agreed to acquire IntraBio for $2 billion in cash, adding the rare-disease biotech's approved drug Aqneursa (levacetylleucine) and its neurodegenerative disease pipeline to Shionogi's growing specialty portfolio. Aqneursa is approved for neurological manifestations of Niemann-Pick disease type C and, following a late-September approval, for ataxia-telangiectasia. The deal follows Shionogi's $2.5 billion acquisition of the ALS drug Radicava from Tanabe Pharma earlier this year, continuing the Japanese drugmaker's push to build a rare-disease franchise beyond its historic infectious-disease base. The transaction, expected to close by year-end, will also give Shionogi access to IntraBio's early-stage programs in Pompe disease, Fragile X syndrome, and Jordan's syndrome.

5 | Gilead Taps Vir’s Masked T-Cell Engager Platform for up to $1.9B | M&A

Vir Biotechnology has entered a collaboration and license agreement with Gilead Sciences to discover and engineer three novel PRO-XTEN dual-masked T-cell engager candidates targeting solid tumor antigens, in a deal worth up to approximately $1.9 billion. Vir will receive $90 million upfront ($65 million cash plus a $25 million equity investment at a 30% premium) and up to $45 million in near-term preclinical milestones, with the remaining $1.74 billion tied to development, regulatory, and commercial milestones plus tiered royalties. Vir will handle discovery, design, and optimization using its PRO-XTEN masking technology and dAIsY AI platform, while Gilead holds the exclusive license to advance, manufacture, and commercialize resulting candidates. This marks Vir's second PRO-XTEN collaboration and Gilead's latest move to build out a T-cell engager franchise following its 2026 acquisition of Ouro Medicines.

6 | CSL Partners with Alentis for up to $1.6B on Rare Kidney and Liver Disease Antibody | M&A

CSL has entered an exclusive global collaboration with Swiss biotech Alentis Therapeutics to co-develop and co-commercialize lixudebart, a first-in-class anti-Claudin-1 antibody for rare kidney and liver diseases, in a deal worth up to $1.6 billion. CSL will pay $355 million upfront and up to $1.2 billion in commercial milestones, while fully funding completion of Alentis's ongoing Phase 2 trial in ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN) as well as planned Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis. Once commercialized, global profits will be split 55% to CSL and 45% to Alentis. Lixudebart previously received FDA orphan drug designation for idiopathic pulmonary fibrosis and is designed to reverse organ damage by targeting Claudin-1-driven fibrosis and inflammation.

7 | AstraZeneca Taps insitro’s AI Platform for up to $1.5B | M&A

AstraZeneca has signed a drug discovery collaboration with AI biotech insitro to apply its Virtual Human platform to target identification in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies, in a deal worth up to $1.5 billion. insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in development and commercial milestones, plus tiered single-digit royalties. Under the agreement, insitro will identify causal disease biology in both indications and advance AstraZeneca-nominated targets from discovery through to development candidate, after which AstraZeneca will lead clinical development, regulatory work, and commercialization. The deal adds AstraZeneca to insitro's roster of Big Pharma collaborators, which also includes Gilead, Bristol Myers Squibb, and Eli Lilly.

8 | Merck KGaA to Acquire Silence Therapeutics for $1.3B | M&A

Merck KGaA has agreed to acquire UK-based Silence Therapeutics in an all-cash deal valued at approximately $1.3 billion in equity value ($1.1 billion enterprise value), paying $20 per American Depositary Share — a 130% premium to the stock's last close. The acquisition gives Merck KGaA Silence's siRNA gene-silencing platform and lead candidate divesiran, which is set to enter Phase 3 development for phlebotomy-dependent polycythemia vera after posting an 88% response rate versus 19% for placebo in a Phase 2 study. The deal is Merck KGaA's third major acquisition in under two years, following its $3.9 billion purchase of SpringWorks Therapeutics and its pending $11.3 billion takeover of Bio-Techne. The transaction, expected to close in the first quarter of 2027, will be effected through a UK scheme of arrangement.

9 | Zealand Partners with Generate Biomedicines for up to $1.2B | M&A

Zealand Pharma has entered a multi-target collaboration and license agreement with Generate Biomedicines to design multispecific protein therapeutics for obesity and other metabolic diseases, in a deal worth up to $1.2 billion. Zealand will pay Generate $30 million upfront for two initial programs, plus up to $35 million in near-term preclinical milestones, with the remainder tied to development, regulatory, and commercial milestones; Zealand also holds an option to add a third program. The collaboration uses Generate's AI-driven protein engineering platform to design multispecific candidates, extending Zealand's modality toolkit beyond its traditional peptide and small-molecule pipeline, which already includes Roche- and Boehringer Ingelheim-partnered obesity assets. Zealand's chief scientific officer described the deal as opening new approaches to polypharmacology for metabolic disease.

10 | Roche Licenses Rona’s ALK7 RNAi Candidate for up to $1.16B | M&A

Roche has licensed exclusive worldwide rights to Rona Therapeutics' investigational RNA interference (RNAi) candidate targeting ALK7 (activin receptor-like kinase 7) for obesity and metabolic diseases, in a deal worth up to $1.16 billion. Rona will receive up to $100 million in upfront and near-term milestone payments, with an additional $1.06 billion tied to development, regulatory, and commercial milestones, plus tiered royalties on global sales. The candidate, built on Rona's extrahepatic RNAi delivery platform, targets a gene linked in human genetic studies to reduced abdominal obesity, joining a growing field of ALK7-directed obesity programs from Alnylam, Arrowhead, and GSK. The deal extends Roche's broader obesity push, which began with its $2.7 billion acquisition of Carmot Therapeutics and now includes partnerships with Hanmi Pharm and Zealand Pharma.

11 | Eli Lilly Partners with Metis TechBio for up to $1.1B | M&A

Eli Lilly has formed a collaboration with Hong Kong-listed Metis TechBio worth up to $1.1 billion to apply Metis's AI-driven ionizable lipid discovery platform to the design of next-generation lipid nanoparticles (LNPs) for tissue-targeted drug delivery. Metis will receive an upfront payment in the low double-digit millions of dollars plus up to approximately $1.1 billion in development, regulatory, and commercial milestones, along with tiered single-digit royalties on net sales. The partnership aims to improve the tissue specificity and biodistribution of LNP-based therapies, an area Lilly has prioritized through a string of delivery-technology deals this year, including a partnership with QurCan Therapeutics and the acquisition of Orna Therapeutics. The collaboration adds Metis to a short list of lipid nanoparticle platforms gaining large-pharma validation beyond mRNA vaccines.

12 | City Therapeutics Raises $200M in Upsized IPO | IPO

City Therapeutics priced an upsized initial public offering of 11.1 million shares at $18.00 per share — the midpoint of its range — for gross proceeds of approximately $200 million, up from the ~$175 million it had previously targeted. The Cambridge, Massachusetts-based company develops next-generation RNA interference (RNAi) therapeutics, with lead programs including CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease, and CITY-TFR2 for anemia of chronic disease. Shares began trading on the Nasdaq Global Market on October 16 under the ticker "CTY" and opened at $23.00, valuing the company at approximately $1.19 billion. Goldman Sachs, Jefferies, Stifel, and Oppenheimer & Co. acted as joint bookrunners.

13 | Iambic Therapeutics Raises $150M in IPO | IPO

Iambic Therapeutics’ initial public offering came in on target, with the company selling 9,375,000 shares at $16.00 apiece — the midpoint of its $15–$17 range — for gross proceeds of $150 million to fund clinical development of the AI biotech’s oncology pipeline. The company uses generative AI and physics-based modeling to design small-molecule cancer drugs, and plans to use proceeds to advance its lead candidates through ongoing clinical trials. NVIDIA, a shareholder, held roughly 9.6 million shares ahead of the offering. Shares began trading on the Nasdaq shortly after pricing.

14 | TRex Bio Raises $116.7M in IPO | IPO

TRex Bio, an Eli Lilly-backed clinical-stage biotech focused on tissue Treg biology, priced its IPO at $14.00 per share — the bottom of its range — selling 8,333,334 shares for gross proceeds of approximately $116.7 million. The company is developing immunoregulatory medicines, including lead candidate TRB-061 for atopic dermatitis, designed to restore immune balance directly in affected tissue. Shares began trading on the Nasdaq Global Select Market on October 9 under the ticker "TRXB," with investors including Eli Lilly, SV Health Investors, Pfizer Ventures, and Johnson & Johnson Innovation. The offering closed on October 13.

15 | Retension Pharmaceuticals Raises $45M in IPO | IPO

Retension Pharmaceuticals, a hypertension-focused biotech, raised $45 million in an upsized IPO, selling 3,750,000 shares at $12.00 apiece — the midpoint of its $11–$13 range — pricing more modestly than fellow Nasdaq debutant TRex Bio on the same day ($116.7 million). The company’s single lead candidate, RTN-001, is a once-daily oral PDE5 inhibitor for uncontrolled and resistant hypertension, in-licensed from Sanofi and currently in a Phase 2b trial; proceeds will fund that trial’s completion and preparation for Phase 3. Shares began trading on the Nasdaq Capital Market on October 9 under the ticker “RTSN,” and the offering closed October 13.

16 | OMass Therapeutics Raises $310M Series C | VC

OMass Therapeutics has closed an oversubscribed $310 million (£230 million) Series C financing, co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings, with participation from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences alongside existing backers Syncona, GV, and the University of Oxford. Proceeds will advance lead candidate OMS1620, a potential best-in-class melanocortin-2 (MC2) receptor antagonist, through Phase 2 development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. The round — one of the largest European biotech financings of the year — also funds early clinical data generation for a first-in-class SLC15A4 inhibitor in lupus, and brings OMass's total funding raised to approximately $475 million.

17 | Matchpoint Therapeutics Raises $150M Series B | VC

Matchpoint Therapeutics has closed a $150 million Series B, co-led by Nextech Invest and Norwest, to move its lead asset MPT-062 (an oral, first-in-class T-cell modulator for autoimmune and inflammatory diseases built on its covalent “ACE” platform) toward clinical proof-of-concept, with trials set to begin in 2027.

18 | Estuary Biotherapeutics Launches with $103M | VC

Estuary Biotherapeutics has emerged from stealth with $103 million to advance two AAV gene therapies for autosomal dominant polycystic kidney disease (ADPKD), one of the most common inherited kidney disorders. The programs target the two genes behind the disease (PKD1 and PKD2) and pair a known gene therapy modality with kidney-directed delivery designed to reach the nephron directly, with the lead program expected to enter the clinic in 2027.

‍

‍

‍

Other news

1 | OrbiMed Raises $3B Across Two New Funds | VC

OrbiMed has raised $3 billion in commitments across two new private funds: OrbiMed Private Investments X, which secured more than $1.9 billion for U.S. and European life sciences venture capital opportunities, and OrbiMed Asia Partners VI, which raised over $1 billion for healthcare growth equity and venture capital investments across Asia. Both funds will target biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services. The Asia-focused vehicle is notably larger than its $751 million and $800 million predecessors, reflecting rising investor interest in the region's life sciences sector — a trend also seen in TCGX's new $600 million Asia fund this month. OrbiMed now manages over $21 billion in healthcare-focused assets.

2 | Forbion Raises €2.3B ($2.6B) Across Two Funds, Its Largest Ever | VC

Forbion has closed €2.3 billion ($2.6 billion) across two new funds — Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII — marking the largest fundraise in the 20-year-old European life sciences VC firm's history and exceeding its 2024 haul of €2 billion. The capital will support roughly 30 "high potential" biotechs, with some investments already completed, including Sling Therapeutics and Solstice Oncology. Investors in the new funds include Eli Lilly, Dutch pension managers MN and PGGM, Germany's KfW Capital, and the Kauffman Foundation. The raise brings Forbion's total assets under management to approximately €7.5 billion ($8.5 billion), cementing its position as Europe's largest dedicated life sciences VC firm.

3 | TCGX Launches $600M Asia Life Sciences Fund | VC

Investment firm TCGX has raised $600 million for its first dedicated Asia life sciences fund, establishing offices in Shanghai and Hong Kong to deploy capital into biotechs emerging from the region's expanding drug discovery hubs. The fund is TCGX's latest expansion beyond its core U.S.-focused life sciences investing. TCGX separately announced this month that its SPAC, TCGX Acquisition Corp., will take migraine-focused biotech TriGemX Bio public (expected to close in Q1 2027), underscoring the firm’s growing footprint across both private and public biotech markets.